Gilead Sciences (GILD) Reports Q2 EPS of $0.49
More News related to GILD
- Gilead (GILD) Lower On Fears of Flat HIV Growth Cited in BofA Downgrade, Another Analyst Takes Opposing View
- Notable Analyst Rating Changes 9/2: AMLN, LOW, GOOG Upgraded; GILD, DF, NSC Downgraded
- David Moenning's Daily State of the Markets: 9/2
- Banc of America Downgrades Gilead Sciences (GILD) to Neutral
- BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
More News related to Earnings
- Shiloh Industries (SHLO) Tops Q3 EPS View By 12c
- National Semiconductor (NSM) Reports Q1 EPS of $0.33; Guides Q2 Sales
- Aceto Corp. (ACET) Reports Q4 EPS of $0.32
- Sycamore Networks (SCMR) Misses Q4 Revenue View By $10M
- ABM Industries (ABM) Reports Higher Q3 Earnings; Narrows FY08 Guidance
Gilead Sciences (Nasdaq: GILD) reports Q2 EPS of $0.49, 1 cent better than the analyst estimate of $0.48. Revenues for the quarter were $1.28 billion, versus the consensus of $1.24 billion.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
EarningsStocks Mentioned
-1.62Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
